Peer-influenced content. Sources you trust. No registration required. This is HCN.

Features:
CME JOBS OUTBREAKS PEER-TO-PEER QUIZZES & QUESTIONS MEDTECH

Anlotinib Prolongs OS in RAS, KRAS, BRAF-Wildtype Metastatic CRC

According to research presented at the virtual ASCO GI Cancers Symposium from the phase 3 ALTER0703 trial, anlotinib was beneficial in Chinese patients with refractory metastatic colorectal cancer (CRC), with particular overall survival (OS) improvement – the primary endpoint – among patients with RAS/KRAS/BRAF-wildtype.

Was this Essential useful?

More Essentials From

ACP Internist
Annals of Internal Medicine
British Medical Journal (The BMJ)
Cancer Therapy Advisor
Cleveland Clinic Journal of Medicine
Clinical Advisor
Consultant360
Dana-Farber Cancer Institute
Epoch Health
Healthgrades for Professionals
MDLinx
Neurology Advisor
Oncology Learning Network
Oncology News Central (ONC)
Psych Congress Network
Psychiatrist.com
The New England Journal of Medicine
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form